What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib
Investor presentation to highlight novel gene therapies for cancer and diabetes
Investor presentations to highlight novel gene therapies for cancer and diabetes
Designed and Secured by Barsec